OmniAb, Inc. (OABI)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
OmniAb Q1 Earnings Call Highlights
OmniAb NASDAQ: OABI reported first-quarter 2026 results that management characterized as a “very strong start to the year,” driven primarily by clinical progress across its partner portfolio and associated milestone revenue. Get OmniAb alerts:Sign UpPartner program progress drives revenue outperformance President and CEO Matt Foehr said the company continues to see partner programs derived from OmniAb's technologies move into the clinic and into later-stage development, which he described as the point where the licensing model translates into “clearer and more visible value” through potential future milestones and royalties.
OmniAb, Inc. (OABI) Reports Q1 Loss, Tops Revenue Estimates
OmniAb, Inc. (OABI) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.17 per share a year ago.
OmniAb, Inc. (OABI) Q4 2025 Earnings Call Transcript
OmniAb, Inc. (OABI) Q4 2025 Earnings Call Transcript
OmniAb, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 3 | $5.55 | $6.31 | $0.76 | 13.69% |
| BG Bart Gancher Intech Investment Management LLC | 28,937 | $69,448.8 | $60,327.86 | -$9,120.94 | -13.13% |
 Point72 Asset Management LP Point72 Asset Management LP | 16,238 | $25,494 | $33,369.09 | $7,875.09 | 30.89% |
 Joseph Castro Nuveen LLC | 623,876 | $1.03M | $1.29M | $255,789.05 | 24.8% |
 Bobby Adusumilli SJS Investment Consulting Inc. | 3 | $4.71 | $6.11 | $1.4 | 29.72% |
OmniAb, Inc. (OABI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has OmniAb, Inc. ever had a stock split?
OmniAb, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Matthew W. Foehr CEO | NASDAQ (NMS) Exchange | 68218J103 CUSIP |
| US Country | 89 Employees | - Last Dividend | - Last Split | 30 Sep 2021 IPO Date |
Overview
OmniAb, Inc. is a pioneering biotechnology company based in the United States that specializes in the discovery and development of therapeutic antibody technologies. Founded in 2012, and with its headquarters in Emeryville, California, the company leverages a unique platform to create and screen a wide array of antibody repertoires. This enables the identification of optimal antibodies to aid the drug development efforts of their partners. OmniAb's cutting-edge technology is underpinned by the biological intelligence of proprietary transgenic animals. These animals, which include OmniRat, OmniChicken, and OmniMouse, have been genetically modified to produce antibodies with human sequences, thus streamlining the development of human therapeutic candidates.
Products and Services
OmniAb, Inc. offers a comprehensive portfolio of technologies and capabilities aimed at advancing therapeutic discovery and development. These include:
- OmniRat, OmniChicken, and OmniMouse: A trio of proprietary transgenic animals genetically engineered to generate antibodies with human sequences. This innovative approach facilitates the development of human therapeutic candidates by ensuring the antibodies produced are more likely to be accepted by the human immune system.
- OmniFlic: A bispecific rat designed for the discovery of bispecific antibody applications. Bispecific antibodies are engineered proteins that can simultaneously bind to two different types of antigen, offering new possibilities in targeted therapy for diseases such as cancer.
- OmniClic: A bispecific chicken that enhances the discovery process of bispecific antibodies, complementing the capabilities provided by OmniFlic and broadening the scope of research into novel therapeutic applications.
- OmniTaur: This technology leverages the unique structural characteristics of cow antibodies to target complex antigens that are difficult to address with traditional antibody technologies. OmniTaur's novel approach opens up new avenues for the creation of therapeutics against a wider range of diseases.
- OmniDeep: A suite of in silico tools, combining AI and machine learning, designed for the therapeutic discovery and optimization process. OmniDeep represents the digital evolution of antibody discovery, offering a faster, more efficient route from conceptualization to candidate identification.
